AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?

World J Urol. 2018 Jan;36(1):149-151. doi: 10.1007/s00345-017-2107-4. Epub 2017 Oct 30.
No abstract available

Publication types

  • Letter

MeSH terms

  • Androgen Receptor Antagonists / therapeutic use
  • Androstadienes / therapeutic use
  • Androstenes / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Benzimidazoles / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Humans
  • Male
  • Nitriles
  • Phenylthiohydantoin / analogs & derivatives
  • Phenylthiohydantoin / therapeutic use
  • Prostate-Specific Antigen / blood
  • Prostate-Specific Antigen / genetics
  • Prostatic Neoplasms, Castration-Resistant / chemistry
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / genetics*
  • RNA Splice Sites / genetics*
  • RNA, Messenger / analysis
  • Randomized Controlled Trials as Topic
  • Receptors, Androgen / analysis
  • Receptors, Androgen / genetics*
  • Treatment Outcome

Substances

  • Androgen Receptor Antagonists
  • Androstadienes
  • Androstenes
  • Antineoplastic Agents
  • Benzamides
  • Benzimidazoles
  • Nitriles
  • RNA Splice Sites
  • RNA, Messenger
  • Receptors, Androgen
  • Phenylthiohydantoin
  • enzalutamide
  • Prostate-Specific Antigen
  • abiraterone
  • 3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene